(Bloomberg) -- Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based ...

Shares of Amgen Inc. soared in premarket trading Friday, after the drug manufacturer posted adjusted earnings above expectations and executives said they are “very encouraged” by preliminary ...

THOUSAND OAKS, Calif., Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 45 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner ...

Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

Also Read: Amgen And Kyowa Kirin’s Rocatinlimab Reduces Eczema Severity In Phase 3 Study Change from baseline in the Quantitative Myasthenia Gravis (QMG) score was also greater for patients in ...

HYDERABAD, India (Reuters) - U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said ...

Amgen announced its plans to open a "technology and innovation" site in India last year that is focused on increasing the use of AI and data science to support development of new medicines.

HYDERABAD, India (Reuters) - U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said at ...